EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC

RTTNews | 410 일 전
EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC

(RTTNews) - eFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 =50%.

Based on 36 events, the hazard ratio for progression free survival (PFS), the primary endpoint of the study, using a stratified Cox proportional hazards model was 0.62 in favor of tomivosertib.

The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p=0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively.

Overall survival results remain immature, however no trend favoring tomivosertib was observed. There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.

read more
China Cuts Loan Prime Rates For First Time In 7 Months

China Cuts Loan Prime Rates For First Time In 7 Months

The People's Bank of China reduced its benchmark interest rate for the first time in seven months to stimulate consumption and support the property market amid soothing trade tensions. The central bank lowered its one-year loan prime rate by 10 basis points to 3.0 percent from 3.10 percent.
RTTNews | 32 분 전
European Shares Likely To Open On Firm Note

European Shares Likely To Open On Firm Note

European stocks may open on a positive note Tuesday as trade tensions continue to ease, and China's central bank cut interest rates to record lows to stimulate the world's second-largest economy challenged by weak consumer demand and a property crisis.
RTTNews | 1 시간 34 분 전
R&M Refresher Instant Milk Tea Powder Recalled

R&M Refresher Instant Milk Tea Powder Recalled

Lakewood, Washington-based R&M Trading LLC is recalling R&M Refresher brand Instant Milk Tea powder products of various flavors as they may contain undeclared milk, a known allergen, the U.S. Food and Drug Administration said. The Instant Milk Tea products are recalled because the ingredients statement declares Whey and Caseinate in Non-Dairy Creamer ingredients, but it does not specify milk.
RTTNews | 1 시간 43 분 전
Australian Market Halves Early Gains In Mid-market

Australian Market Halves Early Gains In Mid-market

The Australian stock market is halving its early gains in mid-market trading on Tuesday, reversing the losses in the previous session, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving well above the 8,300 level, with gains in technology and financial stocks partially offset a mixed performance in mining and energy stocks.
RTTNews | 3 시간 29 분 전